Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.47 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.46 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.46 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | NRP1 | O14786 | 2/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30962076 | 0.92 | GRB2 (0.50) | GRB2NMUR2NMUR1BDKRB2MAPK8 | |
| SCHEMBL30811140 | 0.87 | NMUR2 (0.49) | NMUR2NMUR1MAPK8MAPK9MAPK10 | |
| SCHEMBL29800433 | 0.87 | NRP1 (0.48) | GRB2NMUR2NMUR1BDKRB2NRP1 | |
| SCHEMBL24485493 | 0.87 | F2 (0.49) | GRB2NMUR2NMUR1NRP1CXCR4 | |
| SCHEMBL12237948 | 0.87 | CXCR4 (0.49) | GRB2MAPK8MAPK9MAPK10CXCR4 | |
| SCHEMBL30307576 | 0.86 | NRP1 (0.47) | GRB2NMUR2NMUR1BDKRB2NRP1 | |
| SCHEMBL29629002 | 0.86 | GRB2 (0.50) | GRB2NMUR2NMUR1MAPK8MAPK9 | |
| SCHEMBL29591906 | 0.86 | GRB2 (0.46) | GRB2NMUR2NMUR1BDKRB2NRP1 | |
| SCHEMBL31399622 | 0.85 | NRP1 (0.49) | NMUR2NMUR1NRP1NTSR2NTSR1 | |
| SCHEMBL30855542 | 0.85 | NRP1 (0.49) | NMUR2NMUR1NRP1NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270794-A1 | F-18-LABELED COMPOUND FOR POSITRON EMISSION TOMOGRAPHY OF DEAD CELLS AND PREPARATION METHOD THEREFOR | FUTURECHEM CO., LTD. (KR) | 2024-08-15 | — | — | US | disclosed |
| WO-2022260483-A1 | F-18-LABELED COMPOUND FOR POSITRON EMISSION TOMOGRAPHY OF DEAD CELLS AND PREPARATION METHOD THEREFOR | 서강대학교산학협력단 | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270794-A1 | F-18-LABELED COMPOUND FOR POSITRON EMISSION TOMOGRAPHY OF DEAD CELLS AND PREPARATION METHOD THEREFOR | AIFM1, CASP7, PSEN1 | GRB2 4265/4885NMUR2 3805/4885NMUR1 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.